Introduction

Carney complex (CNC) is a rare, autosomal dominant, multiple neoplasia and lentiginosis syndrome characterised primarily by cutaneous, endocrine, cardiac, neural tumours, and spotty skin pigmentation. One of the less well-known but important aspects of CNC is its association with bone lesions, especially the rare tumour known as osteochondromyxoma, as well as other cartilage and connective tissue anomalies. This essay undertakes a comprehensive review of the biology, clinical manifestations, genetic aetiology, diagnostic features, and clinical implications of bone and cartilage lesions associated with Carney complex. 

Overview of carney complex

Carney complex was first described in 1985 by J.A. Carney and has since become recognised as a distinct entity within the spectrum of multiple endocrine neoplasia (MEN) syndromes. Core clinical components include:

• Spotty skin pigmentation (lentigines, blue nevi)
• Cardiac myxomas
• Endocrine overactivity (notably primary pigmented nodular adrenocortical disease)
• Peripheral nerve tumours (psammomatous melanotic schwannoma)
• Bone and cartilage tumours, chiefly osteochondromyxoma

While more than 1,000 cases of CNC have now been documented worldwide, many cases remain undiagnosed due to variable expressivity and the rarity of the condition.

Genetic basis and molecular pathogenesis

Most cases of Carney complex (over 70%) are due to inactivating mutations in the PRKAR1A gene, which encodes the regulatory subunit type 1α of protein kinase A (PKA). Other genes and loci have occasionally been implicated, including PRKACA, PRKACB, PDE11A, PDE8B, and the CNC2 locus at chromosome 2p16. Loss of PRKAR1A function results in increased PKA activity, which disturbs cell signalling related to proliferation, differentiation, and metabolism, underpinning tumorigenesis in various tissues, including bone.

Bone lesions in carney complex

Osteochondromyxoma: The hallmark bone tumour

Osteochondromyxoma (OMX) is a highly distinctive, though exceptionally rare, bone tumour that is seen almost exclusively in association with Carney complex. Key features include:

• Occurs in approximately 1% of patients with Carney complex, making it one of the rarest manifestations, but one of the eleven clinical diagnostic criteria for the syndrome
• Often presents early in life, sometimes before age two
• Histologically, the tumour contains a mixture of osseous, chondroid, and myxoid elements

OMX can arise from bony cortices and has most frequently been observed in the nasal region, as well as long bones such as the tibia or radius, and even small flat bones. The lesions are typically benign but locally invasive, causing swelling, discomfort, and sometimes bone destruction with possible recurrence after excision.

Pathogenesis

Osteochondromyxoma is believed to originate from mesenchymal stem cells committed to osteoblastic and chondrocytic lineages. Dysregulation of cAMP/PKA signalling, due to PRKAR1A mutations, leads to abnormal proliferation and differentiation of these cells, promoting tumour formation. Mouse models with Prkar1a mutations show analogous bone tumours, supporting this pathogenic mechanism.

Clinical and radiographic features

Radiologically, OMX may appear as radiolucent or mixed-density lesions, sometimes with well-defined margins, and can mimic other bone tumours. Its myxoid content and histological architecture are characteristic of pathological examination.

Other bone tumours and lesions

Although OMX is the classic bone tumour of CNC, other entities have been described:

• Case reports note rare associations with giant cell tumour of bone and other primary osseous tumours in the context of CNC. However, such associations are exceedingly rare, with a handful of case reports in the literature
• Fibrous dysplastic lesions similar to those seen in McCune-Albright syndrome have been described; both syndromes share disruptions in the cAMP/PKA pathway

Cartilage tumours in carney complex

While OMX can exhibit significant cartilaginous differentiation, true isolated cartilaginous (chondroid) tumours directly attributable to Carney complex are exceedingly rare. Most reported instances involve significant myxoid and osteoid proliferation, with cartilaginous elements forming part of the pathological spectrum of OMX.

Histopathology

• Myxoid stroma with embedded cartilage and bone tissue is the hallmark of OMX in CNC
• Chondroid components may be substantial, but are always within the context of the broader osteochondromyxoid tumour

Differential diagnosis

The identification of bony lesions in CNC patients requires a careful differential diagnosis. The rarity of OMX means that other, more common bone tumours, such as conventional osteochondromas, chondromyxoid fibroma, and even malignant entities, must be considered and excluded by histopathology and genetic context.

Diagnostic and clinical implications

Diagnostic criteria and workup

The presence of OMX, while rare, is one of the diagnostic criteria for Carney complex, triggering:

• Comprehensive clinical evaluation for other CNC manifestations (skin, endocrine, heart, neural tissue)
• Genetic testing for PRKAR1A mutations
• Imaging studies (X-ray, CT/MRI) to assess tumour location, invasiveness, and recurrence

Management

Surgical resection is the mainstay of management for symptomatic OMX and other bony tumours. Complete excision generally confers a favourable outcome, though incomplete resection may result in recurrence. Long-term follow-up is warranted due to the potential for recurrence and the late onset of new tumours.

Surveillance

Given the multi-system nature of CNC, patients need lifelong surveillance for other CNC-associated neoplasms, including cardiac myxomas (risk of embolic complications), endocrine tumours (notably adrenal and pituitary), and neural tumours (psammomatous melanotic schwannoma).

Clinical case insights

Numerous case reports illustrate the complexity of diagnosing CNC when bone lesions are the presenting feature. In some cases, initial presentation with a bony tumour such as OMX, in the absence of classic skin or cardiac findings, has delayed a CNC diagnosis until further manifestations appeared. These scenarios underscore the need for clinicians to consider CNC when encountering rare bone lesions like osteochondromyxoma, particularly in young patients or those with subtle features suggestive of a syndromic context.

Pathophysiologic and molecular considerations

The bone lesions of CNC further expand our understanding of how cAMP/PKA signalling operates in bone and cartilage homeostasis. The hyperactivation of PKA appears to drive not only neoplastic proliferation but also influence differentiation patterns of mesenchymal cells. Key pathways involved in cartilage and bone matrix generation, such as Wnt signalling and the PTH/PKA axis, are implicated. A better molecular understanding of these frameworks from CNC research could help illuminate the biology of mesenchymal neoplasms more broadly.

Other tumours and systemic involvement in CNC

CNC is a pan-systemic disease, with significant implications for endocrine (adrenal, pituitary, thyroid, gonadal), neural, and cardiac tissues. Primary pigmented nodular adrenocortical disease (PPNAD) is the most frequent endocrine tumour, present in up to 60% of patients. Cardiac myxomas are observed in roughly 30% of affected individuals and represent a major source of morbidity and mortality due to the risk of embolic events and sudden death. Myxoid skin and soft-tissue tumours, lentigines, blue nevi, and schwannomas further broaden the phenotypic spectrum, emphasising multidisciplinary management for comprehensive care.

Future directions

Recent discoveries of mutations in PRKACA, PRKACB, PDE11A, and PDE8B have broadened the molecular landscape of CNC. As next-generation sequencing becomes more widely available, further novel genotype-phenotype correlations, especially regarding rare tumours like OMX, are expected to be revealed. Moreover, ongoing research is needed to fully delineate the pathways driving cartilage and bone tumour development in the context of cAMP/PKA dysregulation.

Conclusion

Bone lesions, particularly osteochondromyxoma, form a distinctive but rare component of Carney complex. Their identification should prompt a search for systemic features of CNC and appropriate genetic testing. The pathogenesis of these lesions underscores the critical role of the cAMP/PKA axis in bone and cartilage biology. Recognisingg these rare tumours as part of Carney complex has important implications for diagnosis, management, and genetic counselling of patients and affected families.

Summary

Carney complex (CNC) is a rare hereditary syndrome characterised by a spectrum of clinical manifestations, including spotty skin pigmentation, endocrine tumours, cardiac myxomas, and distinct bone and cartilage lesions—most notably osteochondromyxoma (OMX). Although bone involvement is present in a minority of cases, its detection is highly significant, as OMX is virtually pathognomonic for CNC and may serve as an initial clue in undiagnosed patients. 

Genetically, mutations in the PRKAR1A gene lead to aberrant cAMP/PKA signalling, which is central to the pathogenesis not only of endocrine disorders but also of osseous and cartilaginous tumours observed in CNC.

Osteochondromyxomas are typically benign but locally aggressive, affecting mostly younger individuals and involving various skeletal sites. Histologically, these tumours show an admixture of myxoid, osseous, and cartilaginous elements, reflecting the pluripotent mesenchymal origin and disturbed signalling pathways. Whilst other bone and cartilage tumours may rarely be observed, they are much less frequently associated with CNC compared to OMX.

Diagnosis of CNC hinges on a thorough clinical evaluation, recognition of its systemic manifestations, confirmation of genetic mutations, and multidisciplinary care. Surgical excision remains the principal management approach for OMX, with careful follow-up warranted due to the risk of recurrence and occurrence of additional neoplasms in other organ systems.

FAQs

What is carney complex?

Carney Complex (CNC) is a rare genetic disorder characterised by multiple benign tumours, skin pigmentation abnormalities, and endocrine disorders. Bone lesions like osteochondromyxoma are among its rare but key manifestations.

What are the main symptoms of carney complex?

Common symptoms include spotty skin pigmentation (lentigines, blue nevi), cardiac myxomas (heart tumours), endocrine tumours causing hormone imbalances, and occasionally bone lesions such as osteochondromyxoma, which can cause swelling and discomfort.

How common are bone lesions in carney complex?

Bone lesions like osteochondromyxoma are rare, occurring in approximately 1% of CNC patients. Osteochondromyxoma is considered a hallmark tumour when present and is virtually pathognomonic.

What causes carney complex?

Most cases arise due to mutations in the PRKAR1A gene, leading to dysregulation in PKA signalling that promotes tumour formation in multiple tissues, including bone.

How is carney complex diagnosed?

Diagnosis involves clinical evaluation of systemic symptoms, imaging to detect tumours, histopathological analysis of lesions like osteochondromyxoma, and genetic testing to identify mutations in PRKAR1A or related genes.

What does osteochondromyxoma look like, and how is it treated?

Osteochondromyxoma is a benign but locally aggressive bone tumour made of mixed osseous, cartilaginous, and myxoid tissues. Surgical removal is the primary treatment, with careful follow-up necessary to monitor for recurrence.

Can carney complex be inherited?

Yes, CNC is usually inherited in an autosomal dominant pattern, meaning a mutation in just one copy of the gene from a parent can cause the condition. Some cases also arise from new spontaneous mutations.

What other tumours are associated with carney complex?

In addition to bone lesions, patients may develop cardiac myxomas, skin myxomas, endocrine tumours such as primary pigmented nodular adrenocortical disease (PPNAD), and neural tumours like psammomatous melanotic schwannomas.

Is lifelong monitoring necessary?

Yes, because of the risk of new tumours and recurrence of existing ones, lifelong multidisciplinary surveillance is recommended for CNC patients.

Are there any lifestyle changes or treatments to prevent tumour development?

No preventative treatment currently exists. Management focuses on early detection and surgical removal of tumours, along with genetic counselling for affected families.